Overview
Melanotan I corresponds to afamelanotide, a synthetic linear analogue of α-MSH and a selective agonist of the MC1R receptor.
Mechanism of action
MC1R activation stimulates eumelanin synthesis (pigmentation and photoprotection). Its MC1R selectivity distinguishes it from the non-selective Melanotan II.
Research context
Notably: under the trade name SCENESSE® (afamelanotide 16 mg), this molecule is approved (FDA, 2019; EMA) for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), as a subcutaneous implant. The product offered here remains intended for research.
Quality assurance
- Purity ≥ 99 % verified by HPLC
- Certificate of Analysis (COA) available per batch
- Traceability: unique batch number on every vial
Format & handling
Presentation: lyophilised powder, 10 mg / vial · Reconstitution: bacteriostatic water · Storage: refrigerate the lyophilisate; after reconstitution, keep cold and protected from light.
References
- « Afamelanotide for Erythropoietic Protoporphyria », N Engl J Med, 2015 (DOI: 10.1056/NEJMoa1411481).
- SCENESSE® (afamelanotide) authorisations — FDA 2019, EMA.
For research use only. Product intended exclusively for scientific and laboratory research. Not intended for human or animal consumption.
Reviews
There are no reviews yet.